4-Hydroxybutyric Acid
The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dantrolene.
Acepromazine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Acepromazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Aceprometazine.
Advertisement
Alfaxalone
The risk or severity of adverse effects can be increased when Dantrolene is combined with Alfaxalone.
Alfentanil
The risk or severity of adverse effects can be increased when Alfentanil is combined with Dantrolene.
Alphaprodine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Alphaprodine.
Advertisement
Alprazolam
The risk or severity of adverse effects can be increased when Alprazolam is combined with Dantrolene.
Amiodarone
The metabolism of Dantrolene can be decreased when combined with Amiodarone.
Amisulpride
The risk or severity of adverse effects can be increased when Dantrolene is combined with Amisulpride.
Advertisement
Amitriptyline
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Dantrolene.
Amobarbital
The risk or severity of adverse effects can be increased when Amobarbital is combined with Dantrolene.
Amoxapine
The risk or severity of adverse effects can be increased when Amoxapine is combined with Dantrolene.
Apalutamide
The serum concentration of Dantrolene can be decreased when it is combined with Apalutamide.
Aprepitant
The serum concentration of Dantrolene can be increased when it is combined with Aprepitant.
Aripiprazole
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dantrolene.
Articaine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Articaine.
Asenapine
The risk or severity of adverse effects can be increased when Asenapine is combined with Dantrolene.
Atazanavir
The metabolism of Dantrolene can be decreased when combined with Atazanavir.
Atomoxetine
The metabolism of Dantrolene can be decreased when combined with Atomoxetine.
Azelastine
Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Baclofen
The risk or severity of adverse effects can be increased when Baclofen is combined with Dantrolene.
Barbital
The risk or severity of adverse effects can be increased when Dantrolene is combined with Barbital.
Benoxinate
The risk or severity of adverse effects can be increased when Dantrolene is combined with Oxybuprocaine.
Benperidol
The risk or severity of adverse effects can be increased when Dantrolene is combined with Benperidol.
Benzocaine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Benzocaine.
Benzyl Alcohol
The risk or severity of adverse effects can be increased when Dantrolene is combined with Benzyl alcohol.
Boceprevir
The metabolism of Dantrolene can be decreased when combined with Boceprevir.
Bortezomib
The metabolism of Dantrolene can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Dantrolene can be decreased when it is combined with Bosentan.
Brexpiprazole
The risk or severity of adverse effects can be increased when Dantrolene is combined with Brexpiprazole.
Brimonidine
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Bromazepam
The risk or severity of adverse effects can be increased when Bromazepam is combined with Dantrolene.
Bromperidol
The risk or severity of adverse effects can be increased when Dantrolene is combined with Bromperidol.
Brompheniramine
The risk or severity of adverse effects can be increased when Brompheniramine is combined with Dantrolene.
Brotizolam
The risk or severity of adverse effects can be increased when Dantrolene is combined with Brotizolam.
Bupivacaine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Bupivacaine.
Buprenorphine
Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Buspirone
The risk or severity of adverse effects can be increased when Buspirone is combined with Dantrolene.
Butabarbital
The risk or severity of adverse effects can be increased when Butabarbital is combined with Dantrolene.
Butalbital
The risk or severity of adverse effects can be increased when Butalbital is combined with Dantrolene.
Butamben
The risk or severity of adverse effects can be increased when Dantrolene is combined with Butamben.
Butobarbital
The risk or severity of adverse effects can be increased when Dantrolene is combined with Butethal.
Butorphanol
The risk or severity of adverse effects can be increased when Butorphanol is combined with Dantrolene.
Carbamazepine
The metabolism of Dantrolene can be increased when combined with Carbamazepine.
Carbinoxamine
The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dantrolene.
Carisoprodol
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Dantrolene.
Ceritinib
The serum concentration of Dantrolene can be increased when it is combined with Ceritinib.
Cetirizine
The risk or severity of adverse effects can be increased when Cetirizine is combined with Dantrolene.
Chloral Hydrate
The risk or severity of adverse effects can be increased when Dantrolene is combined with Chloral hydrate.
Chlordiazepoxide
The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dantrolene.
Chlormethiazole
The risk or severity of adverse effects can be increased when Dantrolene is combined with clomethiazole.
Chlormezanone
The risk or severity of adverse effects can be increased when Dantrolene is combined with Chlormezanone.
Chloroprocaine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Chloroprocaine.
Chlorpheniramine
The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dantrolene.
CHLORPHENIRAMINE POLISTIREX
The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dantrolene.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dantrolene.
Chlorprothixene
The risk or severity of adverse effects can be increased when Dantrolene is combined with Chlorprothixene.
Chlorzoxazone
The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dantrolene.
Citalopram
The risk or severity of adverse effects can be increased when Dantrolene is combined with Citalopram.
Clarithromycin
The metabolism of Dantrolene can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Dantrolene can be decreased when combined with Clemastine.
Clidinium
The risk or severity of adverse effects can be increased when Clidinium is combined with Dantrolene.
Clidinium bromide
The risk or severity of adverse effects can be increased when Clidinium is combined with Dantrolene.
Clobazam
The risk or severity of adverse effects can be increased when Clobazam is combined with Dantrolene.
Clomipramine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Clomipramine.
Clonazepam
The risk or severity of adverse effects can be increased when Clonazepam is combined with Dantrolene.
Clonidine
The risk or severity of adverse effects can be increased when Clonidine is combined with Dantrolene.
Clorazepate
The risk or severity of adverse effects can be increased when Clorazepate is combined with Dantrolene.
CLORAZEPIC ACID
The risk or severity of adverse effects can be increased when Clorazepate is combined with Dantrolene.
Clotrimazole
The metabolism of Dantrolene can be decreased when combined with Clotrimazole.
Clozapine
The risk or severity of adverse effects can be increased when Clozapine is combined with Dantrolene.
Cobicistat
The metabolism of Dantrolene can be decreased when combined with Cobicistat.
Cocaine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Cocaine.
Codeine
The risk or severity of adverse effects can be increased when Codeine is combined with Dantrolene.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Codeine is combined with Dantrolene.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Codeine is combined with Dantrolene.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Dantrolene.
Crizotinib
The metabolism of Dantrolene can be decreased when combined with Crizotinib.
Cyclizine
The risk or severity of adverse effects can be increased when Cyclizine is combined with Dantrolene.
Cyclobenzaprine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dantrolene.
Cyclosporine
The metabolism of Dantrolene can be decreased when combined with Cyclosporine.
Cyproheptadine
The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Dantrolene.
Dabrafenib
The serum concentration of Dantrolene can be decreased when it is combined with Dabrafenib.
Dapiprazole
The risk or severity of adverse effects can be increased when Dantrolene is combined with Dapiprazole.
Darunavir
The metabolism of Dantrolene can be decreased when combined with Darunavir.
Dasatinib
The serum concentration of Dantrolene can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Dantrolene can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Dantrolene can be decreased when it is combined with Deferasirox.
Delavirdine
The metabolism of Dantrolene can be decreased when combined with Delavirdine.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Dantrolene.
Desipramine
The risk or severity of adverse effects can be increased when Desipramine is combined with Dantrolene.
Desloratadine
The risk or severity of adverse effects can be increased when Desloratadine is combined with Dantrolene.
Desvenlafaxine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Desvenlafaxine.
Dexbrompheniramine
The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dantrolene.
Dexketoprofen
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Dantrolene.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Dexmedetomidine.
Dextromoramide
The risk or severity of adverse effects can be increased when Dantrolene is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Dezocine.
Diazepam
The risk or severity of adverse effects can be increased when Diazepam is combined with Dantrolene.
Dibucaine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Cinchocaine.
Difenoxin
The risk or severity of adverse effects can be increased when Dantrolene is combined with Difenoxin.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dantrolene.
Dihydroergotamine
The metabolism of Dantrolene can be decreased when combined with Dihydroergotamine.
Diltiazem
The metabolism of Dantrolene can be decreased when combined with Diltiazem.
Dimenhydrinate
The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dantrolene.
Diphenhydramine
The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dantrolene.
Diphenoxylate
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dantrolene.
Doxepin
The risk or severity of adverse effects can be increased when Doxepin is combined with Dantrolene.
Doxycycline
The metabolism of Dantrolene can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Dantrolene can be decreased when combined with Doxycycline.
Doxylamine
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Dronedarone
The metabolism of Dantrolene can be decreased when combined with Dronedarone.
Droperidol
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Duloxetine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Duloxetine.
Dyclonine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Dyclonine.
Efavirenz
The risk or severity of adverse effects can be increased when Efavirenz is combined with Dantrolene.
Enflurane
The risk or severity of adverse effects can be increased when Dantrolene is combined with Enflurane.
Entacapone
The risk or severity of adverse effects can be increased when Entacapone is combined with Dantrolene.
Enzalutamide
The serum concentration of Dantrolene can be decreased when it is combined with Enzalutamide.
Erythromycin
The metabolism of Dantrolene can be decreased when combined with Erythromycin.
Escitalopram
The risk or severity of adverse effects can be increased when Dantrolene is combined with Escitalopram.
Estazolam
The risk or severity of adverse effects can be increased when Estazolam is combined with Dantrolene.
Eszopiclone
The risk or severity of adverse effects can be increased when Eszopiclone is combined with Dantrolene.
Ethanol
Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Ethchlorvynol
The risk or severity of adverse effects can be increased when Dantrolene is combined with Ethchlorvynol.
Ethosuximide
The risk or severity of adverse effects can be increased when Ethosuximide is combined with Dantrolene.
Ethotoin
The risk or severity of adverse effects can be increased when Ethotoin is combined with Dantrolene.
Ethyl Chloride
The risk or severity of adverse effects can be increased when Dantrolene is combined with Ethyl chloride.
Ethyl Loflazepate
The risk or severity of adverse effects can be increased when Dantrolene is combined with Ethyl loflazepate.
Ethylmorphine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Ethylmorphine.
Etidocaine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Etidocaine.
Etifoxine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Etifoxine.
Etomidate
The risk or severity of adverse effects can be increased when Dantrolene is combined with Etomidate.
Ezogabine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Ezogabine.
Felbamate
The risk or severity of adverse effects can be increased when Felbamate is combined with Dantrolene.
Fentanyl
The risk or severity of adverse effects can be increased when Fentanyl is combined with Dantrolene.
Fexofenadine
The risk or severity of adverse effects can be increased when Fexofenadine is combined with Dantrolene.
Flibanserin
The risk or severity of adverse effects can be increased when Dantrolene is combined with Flibanserin.
Fluconazole
The metabolism of Dantrolene can be decreased when combined with Fluconazole.
Flunarizine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Flunarizine.
Flunitrazepam
The risk or severity of adverse effects can be increased when Dantrolene is combined with Flunitrazepam.
Fluoxetine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Fluoxetine.
Flupenthixol
The risk or severity of adverse effects can be increased when Flupentixol is combined with Dantrolene.
Fluphenazine
The risk or severity of adverse effects can be increased when Fluphenazine is combined with Dantrolene.
Flurazepam
The risk or severity of adverse effects can be increased when Flurazepam is combined with Dantrolene.
Fluspirilene
The risk or severity of adverse effects can be increased when Dantrolene is combined with Fluspirilene.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dantrolene.
Fluvoxamine
The metabolism of Dantrolene can be decreased when combined with Fluvoxamine.
Fosamprenavir
The metabolism of Dantrolene can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Dantrolene can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The metabolism of Dantrolene can be increased when combined with Fosphenytoin.
Fospropofol
The risk or severity of adverse effects can be increased when Dantrolene is combined with Fospropofol.
Fusidate
The serum concentration of Dantrolene can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Dantrolene can be increased when it is combined with Fusidic Acid.
Gabapentin
The risk or severity of adverse effects can be increased when Gabapentin is combined with Dantrolene.
Gabapentin Enacarbil
The risk or severity of adverse effects can be increased when Dantrolene is combined with Gabapentin Enacarbil.
Glutethimide
The risk or severity of adverse effects can be increased when Dantrolene is combined with Glutethimide.
Guanfacine
The risk or severity of adverse effects can be increased when Guanfacine is combined with Dantrolene.
Halazepam
The risk or severity of adverse effects can be increased when Dantrolene is combined with Halazepam.
Haloperidol
The risk or severity of adverse effects can be increased when Haloperidol is combined with Dantrolene.
Halothane
The risk or severity of adverse effects can be increased when Dantrolene is combined with Halothane.
Heroin
The risk or severity of adverse effects can be increased when Dantrolene is combined with Heroin.
Hexobarbital
The risk or severity of adverse effects can be increased when Dantrolene is combined with Hexobarbital.
Hydrocodone
Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HYDROCODONE POLISTIREX
Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydromorphone
The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dantrolene.
Hydroxyzine
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Hypoxis hemerocallidea root extract
The serum concentration of Dantrolene can be decreased when it is combined with St. John's Wort.
Idelalisib
The metabolism of Dantrolene can be decreased when combined with Idelalisib.
Iloperidone
The risk or severity of adverse effects can be increased when Dantrolene is combined with Iloperidone.
Imatinib
The metabolism of Dantrolene can be decreased when combined with Imatinib.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Dantrolene.
Indinavir
The metabolism of Dantrolene can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Dantrolene can be decreased when combined with Indinavir.
Isavuconazole
The serum concentration of Dantrolene can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Dantrolene can be decreased when combined with Isavuconazonium.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Dantrolene.
Isradipine
The metabolism of Dantrolene can be decreased when combined with Isradipine.
Itraconazole
The metabolism of Dantrolene can be decreased when combined with Itraconazole.
Ivacaftor
The serum concentration of Dantrolene can be increased when it is combined with Ivacaftor.
Ketamine
The risk or severity of adverse effects can be increased when Ketamine is combined with Dantrolene.
Ketazolam
The risk or severity of adverse effects can be increased when Dantrolene is combined with Ketazolam.
Ketoconazole
The metabolism of Dantrolene can be decreased when combined with Ketoconazole.
Lacidipine
The risk or severity of adverse effects can be increased when Lacidipine is combined with Dantrolene.
Lamotrigine
The risk or severity of adverse effects can be increased when Lamotrigine is combined with Dantrolene.
Levetiracetam
The risk or severity of adverse effects can be increased when Levetiracetam is combined with Dantrolene.
Levobupivacaine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Levobupivacaine.
Levocabastine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Levocabastine.
Levocetirizine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Levocetirizine.
Levodopa
The risk or severity of adverse effects can be increased when Dantrolene is combined with Levodopa.
Levomethadyl
The risk or severity of adverse effects can be increased when Dantrolene is combined with Levomethadyl Acetate.
Levomilnacipran
The risk or severity of adverse effects can be increased when Dantrolene is combined with Levomilnacipran.
Levorphanol
The risk or severity of adverse effects can be increased when Levorphanol is combined with Dantrolene.
Lidocaine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Lidocaine.
Lithium
The risk or severity of adverse effects can be increased when Dantrolene is combined with Lithium.
Lithium Cation
The risk or severity of adverse effects can be increased when Dantrolene is combined with Lithium.
Lopinavir
The metabolism of Dantrolene can be decreased when combined with Lopinavir.
Loratadine
The risk or severity of adverse effects can be increased when Loratadine is combined with Dantrolene.
Lorazepam
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dantrolene.
Lormetazepam
The risk or severity of adverse effects can be increased when Dantrolene is combined with Lormetazepam.
Lovastatin
The metabolism of Dantrolene can be decreased when combined with Lovastatin.
Loxapine
The risk or severity of adverse effects can be increased when Loxapine is combined with Dantrolene.
Luliconazole
The serum concentration of Dantrolene can be increased when it is combined with Luliconazole.
Lumacaftor
The metabolism of Dantrolene can be increased when combined with Lumacaftor.
Lurasidone
The risk or severity of adverse effects can be increased when Lurasidone is combined with Dantrolene.
Magnesium Sulfate
The therapeutic efficacy of Dantrolene can be increased when used in combination with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The therapeutic efficacy of Dantrolene can be increased when used in combination with Magnesium sulfate.
Maprotiline
The risk or severity of adverse effects can be increased when Maprotiline is combined with Dantrolene.
Meclizine
The risk or severity of adverse effects can be increased when Meclizine is combined with Dantrolene.
Melatonin
The risk or severity of adverse effects can be increased when Dantrolene is combined with Melatonin.
Meperidine
The risk or severity of adverse effects can be increased when Pethidine is combined with Dantrolene.
Mephobarbital
The risk or severity of adverse effects can be increased when Dantrolene is combined with Methylphenobarbital.
Mepivacaine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Mepivacaine.
Meprobamate
The risk or severity of adverse effects can be increased when Meprobamate is combined with Dantrolene.
Mesoridazine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Mesoridazine.
Metaxalone
The risk or severity of adverse effects can be increased when Metaxalone is combined with Dantrolene.
Methadone
The risk or severity of adverse effects can be increased when Methadone is combined with Dantrolene.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Dantrolene is combined with Methadyl Acetate.
Methapyrilene
The risk or severity of adverse effects can be increased when Dantrolene is combined with Methapyrilene.
Methaqualone
The risk or severity of adverse effects can be increased when Dantrolene is combined with Methaqualone.
Methocarbamol
The risk or severity of adverse effects can be increased when Methocarbamol is combined with Dantrolene.
Methohexital
The risk or severity of adverse effects can be increased when Methohexital is combined with Dantrolene.
Methotrimeprazine
Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Methoxyflurane
The risk or severity of adverse effects can be increased when Dantrolene is combined with Methoxyflurane.
Methsuximide
The risk or severity of adverse effects can be increased when Dantrolene is combined with Methsuximide.
Metylperon
The risk or severity of adverse effects can be increased when Dantrolene is combined with Melperone.
Metyrosine
Dantrolene may increase the sedative activities of Metyrosine.
Midazolam
The risk or severity of adverse effects can be increased when Midazolam is combined with Dantrolene.
Mifepristone
The serum concentration of Dantrolene can be increased when it is combined with Mifepristone.
Milnacipran
The risk or severity of adverse effects can be increased when Dantrolene is combined with Milnacipran.
Minocycline
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Mirtazapine
Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Mitotane
The serum concentration of Dantrolene can be decreased when it is combined with Mitotane.
Molindone
The risk or severity of adverse effects can be increased when Dantrolene is combined with Molindone.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Dantrolene.
Nabilone
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Nalbuphine
The risk or severity of adverse effects can be increased when Nalbuphine is combined with Dantrolene.
Nefazodone
The metabolism of Dantrolene can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Dantrolene can be decreased when combined with Nelfinavir.
Netupitant
The serum concentration of Dantrolene can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Dantrolene can be increased when combined with Nevirapine.
Nilotinib
The metabolism of Dantrolene can be decreased when combined with Nilotinib.
Nitrazepam
The risk or severity of adverse effects can be increased when Nitrazepam is combined with Dantrolene.
Nitrous Oxide
The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dantrolene.
Norflurane
The risk or severity of adverse effects can be increased when Dantrolene is combined with Norflurane.
Normethadone
The risk or severity of adverse effects can be increased when Dantrolene is combined with Normethadone.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Dantrolene.
Olanzapine
The risk or severity of adverse effects can be increased when Olanzapine is combined with Dantrolene.
Olaparib
The metabolism of Dantrolene can be decreased when combined with Olaparib.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Dantrolene.
Ondansetron
The risk or severity of adverse effects can be increased when Dantrolene is combined with Ondansetron.
Opium
The risk or severity of adverse effects can be increased when Dantrolene is combined with Opium.
Orphenadrine
Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Osimertinib
The serum concentration of Dantrolene can be increased when it is combined with Osimertinib.
Oxazepam
The risk or severity of adverse effects can be increased when Oxazepam is combined with Dantrolene.
Oxprenolol
The risk or severity of adverse effects can be increased when Dantrolene is combined with Oxprenolol.
Oxycodone
The risk or severity of adverse effects can be increased when Oxycodone is combined with Dantrolene.
Oxymorphone
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Dantrolene.
Palbociclib
The serum concentration of Dantrolene can be increased when it is combined with Palbociclib.
Paliperidone
The risk or severity of adverse effects can be increased when Paliperidone is combined with Dantrolene.
Paraldehyde
Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Dantrolene.
Paroxetine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Paroxetine.
Pentazocine
The risk or severity of adverse effects can be increased when Pentazocine is combined with Dantrolene.
Pentobarbital
The metabolism of Dantrolene can be increased when combined with Pentobarbital.
Perampanel
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Perazine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Perazine.
Perphenazine
The risk or severity of adverse effects can be increased when Perphenazine is combined with Dantrolene.
Phenobarbital
The metabolism of Dantrolene can be increased when combined with Phenobarbital.
Phenoxyethanol
The risk or severity of adverse effects can be increased when Dantrolene is combined with Phenoxyethanol.
Phenytoin
The metabolism of Dantrolene can be increased when combined with Phenytoin.
Pimozide
The risk or severity of adverse effects can be increased when Pimozide is combined with Dantrolene.
Pipamperone
The risk or severity of adverse effects can be increased when Dantrolene is combined with Pipamperone.
Pipothiazine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Pipotiazine.
Pirinitramide
The risk or severity of adverse effects can be increased when Dantrolene is combined with Piritramide.
Pizotyline
The risk or severity of adverse effects can be increased when Dantrolene is combined with Pizotifen.
Pomalidomide
The risk or severity of adverse effects can be increased when Dantrolene is combined with Pomalidomide.
Posaconazole
The metabolism of Dantrolene can be decreased when combined with Posaconazole.
Pramipexole
Dantrolene may increase the sedative activities of Pramipexole.
Pramoxine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Pramocaine.
Prazepam
The risk or severity of adverse effects can be increased when Dantrolene is combined with Prazepam.
Pregabalin
The therapeutic efficacy of Dantrolene can be increased when used in combination with Pregabalin.
Prilocaine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Prilocaine.
Primidone
The metabolism of Dantrolene can be increased when combined with Primidone.
Procaine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Procaine.
Prochlorperazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dantrolene.
Promazine
The risk or severity of adverse effects can be increased when Promazine is combined with Dantrolene.
Promethazine
The risk or severity of adverse effects can be increased when Promethazine is combined with Dantrolene.
Proparacaine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Proparacaine.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Dantrolene.
Propoxyphene
The risk or severity of adverse effects can be increased when Dantrolene is combined with Dextropropoxyphene.
Protriptyline
The risk or severity of adverse effects can be increased when Protriptyline is combined with Dantrolene.
Quazepam
The risk or severity of adverse effects can be increased when Quazepam is combined with Dantrolene.
Quetiapine
The risk or severity of adverse effects can be increased when Quetiapine is combined with Dantrolene.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Quetiapine is combined with Dantrolene.
Ramelteon
The risk or severity of adverse effects can be increased when Ramelteon is combined with Dantrolene.
Ranolazine
The metabolism of Dantrolene can be decreased when combined with Ranolazine.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Dantrolene.
Remoxipride
The risk or severity of adverse effects can be increased when Dantrolene is combined with Remoxipride.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Dantrolene.
Rifabutin
The metabolism of Dantrolene can be increased when combined with Rifabutin.
Rifampin
The metabolism of Dantrolene can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Dantrolene can be increased when combined with Rifapentine.
Risperidone
The risk or severity of adverse effects can be increased when Risperidone is combined with Dantrolene.
Ropinirole
Dantrolene may increase the sedative activities of Ropinirole.
Ropivacaine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Ropivacaine.
Rotigotine
Dantrolene may increase the sedative activities of Rotigotine.
Rucaparib
The metabolism of Dantrolene can be decreased when combined with Rucaparib.
Rufinamide
The risk or severity of adverse effects can be increased when Rufinamide is combined with Dantrolene.
Saquinavir
The metabolism of Dantrolene can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Dantrolene can be decreased when combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Dantrolene can be decreased when used in combination with Sarilumab.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Dantrolene.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Dantrolene.
Secobarbital
The risk or severity of adverse effects can be increased when Secobarbital is combined with Dantrolene.
Sertindole
The risk or severity of adverse effects can be increased when Dantrolene is combined with Sertindole.
Sertraline
The risk or severity of adverse effects can be increased when Dantrolene is combined with Sertraline.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Dantrolene.
Sildenafil
The metabolism of Dantrolene can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Dantrolene can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Dantrolene can be increased when it is combined with Simeprevir.
Sodium Oxybate
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
ST. JOHN'S WORT EXTRACT
The serum concentration of Dantrolene can be decreased when it is combined with St. John's Wort.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Dantrolene.
Sulfisoxazole
The metabolism of Dantrolene can be decreased when combined with Sulfisoxazole.
Sulpiride
The risk or severity of adverse effects can be increased when Dantrolene is combined with Sulpiride.
Suvorexant
Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Tasimelteon
The risk or severity of adverse effects can be increased when Dantrolene is combined with Tasimelteon.
Telaprevir
The metabolism of Dantrolene can be decreased when combined with Telaprevir.
Telithromycin
The metabolism of Dantrolene can be decreased when combined with Telithromycin.
Temazepam
The risk or severity of adverse effects can be increased when Temazepam is combined with Dantrolene.
Tetrabenazine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Tetrabenazine.
Tetracaine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Tetracaine.
Tetracaine hydrochloride
The risk or severity of adverse effects can be increased when Dantrolene is combined with Tetracaine.
Tetrahydrocannabinol
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Thalidomide
Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Thiamylal
The risk or severity of adverse effects can be increased when Dantrolene is combined with Thiamylal.
Thiopental
The risk or severity of adverse effects can be increased when Dantrolene is combined with Thiopental.
Thiopental Sodium
The risk or severity of adverse effects can be increased when Dantrolene is combined with Thiopental.
Thioridazine
The risk or severity of adverse effects can be increased when Thioridazine is combined with Dantrolene.
Thiothixene
The risk or severity of adverse effects can be increased when Thiothixene is combined with Dantrolene.
Tiagabine
The risk or severity of adverse effects can be increased when Tiagabine is combined with Dantrolene.
Tiapride
The risk or severity of adverse effects can be increased when Dantrolene is combined with Tiapride.
Ticlopidine
The metabolism of Dantrolene can be decreased when combined with Ticlopidine.
Tizanidine
The risk or severity of adverse effects can be increased when Tizanidine is combined with Dantrolene.
Tocilizumab
The serum concentration of Dantrolene can be decreased when it is combined with Tocilizumab.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Dantrolene.
Topiramate
The risk or severity of adverse effects can be increased when Topiramate is combined with Dantrolene.
Tramadol
The risk or severity of adverse effects can be increased when Tramadol is combined with Dantrolene.
Tranylcypromine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Tranylcypromine.
Trazodone
The risk or severity of adverse effects can be increased when Dantrolene is combined with Trazodone.
Triazolam
The risk or severity of adverse effects can be increased when Triazolam is combined with Dantrolene.
Triazulenone
The risk or severity of adverse effects can be increased when Dantrolene is combined with Loprazolam.
Trifluoperazine
The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dantrolene.
Triflupromazine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Triflupromazine.
Trimipramine
The risk or severity of adverse effects can be increased when Trimipramine is combined with Dantrolene.
Triprolidine
The risk or severity of adverse effects can be increased when Triprolidine is combined with Dantrolene.
Urethane
The risk or severity of adverse effects can be increased when Dantrolene is combined with Ethyl carbamate.
Valproate
The risk or severity of adverse effects can be increased when Dantrolene is combined with Valproic Acid.
Valproic Acid
The risk or severity of adverse effects can be increased when Dantrolene is combined with Valproic Acid.
Vecuronium
Dantrolene may increase the neuromuscular blocking activities of Vecuronium.
Vemurafenib
The serum concentration of Dantrolene can be decreased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Dantrolene can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Dantrolene can be decreased when combined with Verapamil.
Vigabatrin
The risk or severity of adverse effects can be increased when Vigabatrin is combined with Dantrolene.
Voriconazole
The metabolism of Dantrolene can be decreased when combined with Voriconazole.
Vortioxetine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Vortioxetine.
Zaleplon
The risk or severity of adverse effects can be increased when Zaleplon is combined with Dantrolene.
Ziconotide
The risk or severity of adverse effects can be increased when Dantrolene is combined with Ziconotide.
Ziprasidone
The metabolism of Dantrolene can be decreased when combined with Ziprasidone.
Zolpidem
Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zonisamide
The risk or severity of adverse effects can be increased when Zonisamide is combined with Dantrolene.
Zopiclone
The risk or severity of adverse effects can be increased when Zopiclone is combined with Dantrolene.
Zotepine
The risk or severity of adverse effects can be increased when Dantrolene is combined with Zotepine.
Zuclopenthixol
The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dantrolene.
